Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cholestin research

This article was originally published in The Tan Sheet

Executive Summary

Study by David Heber, MD/PhD, UCLA Center for Human Nutrition, showing an average 22% reduction in LDL-cholesterol concentration in subjects taking red yeast rice is published in the February issue of the American Journal of Clinical Nutrition. Results were earlier presented by Heber at an April 1998 scientific conference ("The Tan Sheet" April 27, 1998, p. 14). The 12-week, placebo-controlled study involved 83 subjects. In an accompanying editorial entitled "Dietary Supplement or Drug? The Case of Cholestin," Richard Havel, University of California at San Francisco, notes no data are available on the short- or long-term toxicity of the individual statins in Cholestin except for lovastatin. Havel was a member of the scientific advisory board of Merck Therapeutic Institute from 1985 to 1990 and participated in clinical trials of lovastatin, marketed by Merck as the Rx cholesterol reducing drug Mevacor

You may also be interested in...



People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

PS089410

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel